Shanghai Serum Bio-Technology Co., Ltd. (SHA:688163)

SHA:688163 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	79.08	33.28	182.11	150.92	515.73	115.88
Short-Term Investments	-	10.63	9.26	-	-	-
Trading Asset Securities	644.97	764.91	641.21	722.59	417.62	65.15
Cash & Short-Term Investments	724.05	808.82	832.58	873.51	933.35	181.03
Cash Growth	-7.91%	-2.85%	-4.69%	-6.41%	415.59%	53.10%
Accounts Receivable	95.52	46.1	36.68	22.63	7.68	9.59
Other Receivables	1.16	0.9	0.86	0.8	0.98	6.25
Receivables	96.68	47	37.54	23.43	8.66	15.84
Inventory	37.13	43.03	43.28	44.75	54.53	49.18
Other Current Assets	24.06	13.31	2.97	7.24	0.51	1.89
Total Current Assets	881.93	912.16	916.36	948.93	997.05	247.93
Property, Plant & Equipment	276.72	200.96	157.34	127.82	117.42	103.67
Long-Term Investments	-	-	-	16.59	17.35	19.81
Other Intangible Assets	21.89	22.47	23.03	23.79	24.24	23.97
Long-Term Deferred Tax Assets	7.26	6.89	8	9.91	9.29	5.09
Long-Term Deferred Charges	0.21	0.39	0.63	0.87	1.11	1.35
Other Long-Term Assets	4.13	14.34	14.66	0.55	0.02	1.06
Total Assets	1,192	1,157	1,120	1,128	1,166	402.89

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	26.08	16.49	1.31	3.64	4.28	2.47
Accrued Expenses	7.89	15.13	14.57	16.92	17.05	11.48
Current Portion of Leases	-	0.77	0.29	0.76	1.37	1.33
Current Income Taxes Payable	9.64	-	-	-	1.51	0.4
Current Unearned Revenue	2.54	3.18	2.2	2.93	1.99	1.44
Other Current Liabilities	2.29	1.33	1.24	0.75	0.68	0.53
Total Current Liabilities	49.18	36.91	19.62	24.99	26.87	17.65
Long-Term Leases	3.84	4.33	4	12.2	12.31	13.02
Long-Term Deferred Tax Liabilities	1.43	1.28	0.91	5.45	5.67	2.59
Other Long-Term Liabilities	3.08	2.04	-	-	-	-
Total Liabilities	57.53	44.55	24.53	42.63	44.86	33.26

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	108.22	108.22	108.22	108.22	108.22	81.16
Additional Paid-In Capital	878.09	878.09	878.09	878.09	871.49	113.62
Retained Earnings	148.3	126.35	109.19	99.53	141.92	174.84
Total Common Equity	1,135	1,113	1,096	1,086	1,122	369.63
Shareholders' Equity	1,135	1,113	1,096	1,086	1,122	369.63
Total Liabilities & Equity	1,192	1,157	1,120	1,128	1,166	402.89

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	4.59	5.1	4.3	12.96	13.68	14.35
Net Cash (Debt)	719.47	803.73	828.28	860.55	919.66	166.68
Net Cash Growth	-8.03%	-2.96%	-3.75%	-6.43%	451.75%	40.97%
Net Cash Per Share	6.67	7.45	7.67	7.99	9.02	2.05
Filing Date Shares Outstanding	110.17	108.22	108.22	108.22	108.22	81.16
Total Common Shares Outstanding	110.17	108.22	108.22	108.22	108.22	81.16
Working Capital	832.75	875.25	896.74	923.94	970.18	230.29
Book Value Per Share	10.30	10.28	10.12	10.03	10.36	4.55
Tangible Book Value	1,113	1,090	1,072	1,062	1,097	345.66
Tangible Book Value Per Share	10.10	10.07	9.91	9.81	10.14	4.26
Buildings	-	127.63	121.51	64.9	60.97	58.87
Machinery	-	79.32	71.64	67.04	62.65	55.95
Construction In Progress	-	80.99	41.84	54.6	43.14	29.52

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 3, 2026

Data Sources Report a data error